An analysis of PARTNER 2 data, published in the June edition of the Journal of the American College of Cardiology, suggests transcatheter aortic valve replacement (TAVR) within failed bioprosthetic surgical aortic valves is a viable long-term solution for high-risk individuals, with patients seeing “excellent” functional and quality of life outcomes three years after the procedure.